Envalior publishes its first Sustainability Report
Envalior today publishes its Sustainability Report, reinforcing its commitment to transparent reporting and providing detailed insights into the company’s... Read more.
Strathcona Resources Ltd. Announces Amended and Extended Offer to Acquire MEG Energy Corp.
CALGARY, AB, Sept. 8, 2025 /PRNewswire/ – Strathcona Resources Ltd. (“Strathcona“) today announced a variation and extension of its previously... Read more.
SPJIMR retains #35 global rank, among top 3 in India in FT MiM 2025 global ranking
Ranked #1 in Careers Service among Indian B-schools (Global Rank: #3) MUMBAI, India, Sept. 8, 2025 /PRNewswire/ — Bharatiya Vidya Bhavan’s S.P. Jain... Read more.
Backpack EU Goes Live, Offering Regulated Perpetuals Trading for European Traders
NICOSIA, Cyprus, Sept. 8, 2025 /PRNewswire/ — Backpack Exchange, a fully regulated global cryptocurrency exchange, today announced the launch of perpetual... Read more.
DuRoBo Debuts Krono: A 6.13″ ePaper Focus Hub for Clarity and Calm
NEW YORK, Sept. 8, 2025 /PRNewswire/ — DuRoBo unveils Krono, its trailblazing first device, a 6.13″ ePaper focus hub designed to acquire knowledge, store... Read more.
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable... Read more.
Kea Raises €6M in Extended Seed Round at €40M Valuation to Scale Its Crypto-Friendly Core Banking Infrastructure
NICOSIA, Cyprus, Sept. 8, 2025 /PRNewswire/ — At SiGMA Euro-Med 2025 in Malta, Kea is showcasing its flagship payment solutions and joining the stage in... Read more.
Gushengtang’s H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ — On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and... Read more.
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily... Read more.
Repurchase of Truecaller B shares in week 36, 2025
STOCKHOLM, Sept. 8, 2025 /PRNewswire/ — During 1 September 2025 and 5 September 2025 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in... Read more.